Endothelial dysfunction in patients with ischemic stroke


如何引用文章

全文:

详细

There are different pathogenetic mechanisms underlying the polimorphism of the ischemic stroke (atherothrombosis, cardiocerebral emboly, small vessels changes in arterial hypertension). Among these mechanisms one of the key places belongs to the disturbances of the endothelial function and haemostatic system. Today, endothelial dysfunction is believed to be a crucial step in the pathogenesis of arterial hypertension and atherosclerosis, as well as of their complications, such as ischemic stroke. The aim of this study was to evaluate the endothelial function in patients with acute ischemic stroke using biochemical (level of antithrombin III, von Willebrand factor) and ultrasound (test on endothelial derived vasodilatation of the brachial artery) methods. It was shown that ischemic stroke occurs in the case of dysbalance of endothelial production of substances with procoagulant activity (increase in level of the von Willebrand factor) and anticoagulant activity (decrease in the antithrombin III level), i.e. they occur in the situation of endothelial dysfunction. The ultrasound markers of endothelial dysfunction were also demonstrated in patients with ischemic stroke. The endothelial dysfunction is maximal in acute phase of ischemic stroke, it takes place in all stroke subtypes and is correlated with the degree of neurological deficit.

 
 

作者简介

Z. Suslina

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

编辑信件的主要联系方式.
Email: platonova@neurology.ru
俄罗斯联邦

M. Tanashyan

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
俄罗斯联邦

M. Domashenko

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
俄罗斯联邦

V. Ionova

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
俄罗斯联邦

A. Chechetkin

Research Center of Neurology, Russian Academy of Medical Sciences, Moscow

Email: platonova@neurology.ru
俄罗斯联邦

参考

  1. Балуда В.П., Соколов Е.И., Балуда М.В. и др. Манжеточная проба в диагностике функционального состояния сосудистого звена системы гемостаза. Гематология и трансфузиология 1987; 9: 51–53.
  2. Бувальцев В.И. Дисфункция эндотелия как новая концепция профилактики и лечения сердечно-сосудистых заболеваний. Междунар. мед. журн. 2001; 3: 202–208.
  3. Власова И.В., Ваизова О.Е., Федосова Н.Н. и др. Состояние эндотелий зависимой вазодилатации у больных цереброваскулярной болезнью. Клин. мед. 2000; 78: 26–29.
  4. Воскобой И.В., Семенов А.В., Мазуров А.В. и др. Активность тромбоцитов и функциональное состояние эндотелия у больных с нестабильной стенокардией с благоприятным и неблагоприятным исходом (проспективное исследование). Кардиология 2002; 42: 4–11.
  5. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция. / Под ред. Н.Н. Петрищева. СПб.: Изддво СПбГМУ, 2003.
  6. Лутай М.И., Голикова И.П., Деяк С.И. и др. Взаимосвязь фактора Виллебранда с сосудодвигательной функцией эндотелия у больных с разной степенью выраженности атеросклероза венечных артерий. Украинский кардиологический журнал 2003; 6: 1–6.
  7. Сидоренко Б.А., Затейщиков Д.А. Дисфункция эндотелия в патогенезе атеросклероза и его осложнений. Кремлевская медицина 1999; 2: 51–54.
  8. Суслина З.А., Танашян М.М., Ионова В.Г. Концепция дизрегуляции гемостаза как универсального фактора патогенеза ишемического инсульта. Материалы IX всероссийского съезда неврологов 2006: 489.
  9. Суслина З.А., Танашян М.М., Ионова В.Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. М.: Медицинская книга, 2005.
  10. Танашян М.М. Ишемические инсульты и основные характеристики гемореологии, гемостаза и фибринолиза. Дис. … докт. мед. наук. М., 1997.
  11. Танашян М.М. Гемостаз, гемореология и атромбогенная активность сосудистой стенки в ангионеврологии. Анн. клин. и экспее рим. неврол. 2007; 2: 29–33.
  12. Шутов А.А., Байдина Т.В., Агафонов А.В. и др. Дисфункция эндотелия у больных с ишемическим инсультом. Журн. неврол. и психиатрии им. С.С. Корсакова 2005; 14: 42–45.
  13. Bonetti P.O., Lerman L.O., Lerman A. et al. Endothelial dysfunction. A marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 168–175.
  14. Boneu B., Abbal M., Plante J. et al. Factor VIII complex and endothelial damage. Lancet 1975; 30: 325–333.
  15. Celermajer D.S., Sorensen K.E., Georgakopoulos D. et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149–2155.
  16. Cherian P., Hankey G.J., Eikelboom J.W. et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003; 34: 2132–2137.
  17. Cushman M., Lemaitre R.N., Kuller L.H. et al. Fibrinolytic activation markers predict myocardial infarction in the elderly: the Cardiovascular Health study. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 493–498.
  18. Esper R.J., Nordaby R.A., Vilarino J.O. et al. Endothelial dysfunction: a comprehensive appraisal. Cardiovascular Diabetology 2006; 5: 4.
  19. Giroud M., Dutrillaux F., Lemesle M. Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different. Neurol. Res. 1998; 20: 15–18.
  20. Hossman V., Heiss W.D., Bewermeyer H. Antithrombin deficiency in ischemic stroke. Klin. Wochenschr. 1983; 61: 617–620.
  21. Kozuka K., Kohriyama T., Nomura E. et al. Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype. Atherosclerosis 2002; 161: 161–168.
  22. Lip G.Y., Blann A.D., Farooqi I.S. et al. Sequential alterations in hemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagulation and Fibrinolysis 2002; 13: 339–347.
  23. Montalescot G., Philippe F., Vicaut E. and the French Investigators of the ESSENCE Trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Circulation 1998; 98: 294–299.
  24. Neunteufl T., Heher S., Katzenschlager R. et al. Late prognostic value of flow mediated dilation in the brachial artery of patients with chest pain. Am. J. Cardiol. 2000; 86: 207–210.
  25. Noto A.T., Mathiesen B.E., Amiral J. et al. Endothelial dysfunction and systemic inflammation in persons with echolucent carotid plaques. Thrombosis and Haemostasis 2006; 96: 53–59.
  26. Pankiewicz J., Iskra T., Slowik A. et al. Markers of endothelial damage are different in stroke due to large and small vessel disease. Cerebrovasc. Dis. 2002; 13 (suppl. 3): 39.
  27. Roldan V., Marin F., Garcia-Herola A., Lip G.Y. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point based stroke risk stratification scores in atrial fibrillation. Thrombosis Research 2005; 116: 321–325.
  28. Vischer U.M. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J. of Thrombosis and Haemostasis 2006; 4: 1186–1193.
  29. Verma S., Anderson T. J. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546–549.
  30. Widlansky M.E., Gokce N., Keaney J.F., Vita J.A. The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol. 2003; 42: 1149–1160.
  31. Yang Z., Ming X.F. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res. 2006; 1: 53–65.

版权所有 © Suslina Z.A., Tanashyan M.M., Domashenko M.A., Ionova V.G., Chechetkin A.O., 2008

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##